{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:27:23Z","timestamp":1779935243989,"version":"3.53.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["101126\/B\/13\/Z"],"award-info":[{"award-number":["101126\/B\/13\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["101126\/Z\/13\/Z"],"award-info":[{"award-number":["101126\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["GAUK 998217"],"award-info":[{"award-number":["GAUK 998217"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GACR 17\\u201312816S"],"award-info":[{"award-number":["GACR 17\\u201312816S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.tox.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T11:43:26Z","timestamp":1553341406000},"page":"40-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells"],"prefix":"10.1016","volume":"419","author":[{"given":"Radek","family":"Indra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"\u010cern\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbyn\u011bk","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hrab\u011bta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Dost\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u017eb\u011bta","family":"Leng\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0865-8785","authenticated-orcid":false,"given":"Mark\u00e9ta","family":"Mart\u00ednkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Eckschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz H.","family":"Schmeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker M.","family":"Arlt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Stiborov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2019.03.009_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/156800911794328493","article-title":"Advances in nano drugs for cancer chemotherapy","volume":"11","author":"Ali","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.tox.2019.03.009_bib0010","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1021\/acs.molpharmaceut.6b00465","article-title":"Image-guided radiotherapy targets macromolecules through altering the tumor microenvironment","volume":"13","author":"Appelbe","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tox.2019.03.009_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(87)90463-2","article-title":"Multimodal action of antitumor agents on DNA: the ellipticine series","volume":"259","author":"Auclair","year":"1987","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.tox.2019.03.009_bib0020","doi-asserted-by":"crossref","first-page":"13391","DOI":"10.3390\/ijms140713391","article-title":"Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery","volume":"14","author":"Blazkova","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1135\/cccc2009525","article-title":"Cytochrome P450 3A activities and their modulation by alpha-naphthoflavone in vitro are dictated by the efficiencies of model experimental systems","volume":"75","author":"Bo\u0159ek-Dohalsk\u00e1","year":"2010","journal-title":"Coll. Czech. Chem. Commun."},{"key":"10.1016\/j.tox.2019.03.009_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-2797(01)00263-0","article-title":"Alpha-naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6","volume":"138","author":"Bo\u0159ek-Dohalsk\u00e1","year":"2001","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tox.2019.03.009_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.phrs.2010.01.014","article-title":"Magnetic nanoparticles and targeted drug delivering","volume":"62","author":"Chomoucka","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tox.2019.03.009_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-60327-198-1_6","article-title":"Zeta potential measurement","volume":"697","author":"Clogston","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2019.03.009_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc.2017.77","article-title":"Tumour acidosis: from the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tox.2019.03.009_bib0050","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.1021\/acsami.6b04286","article-title":"Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells","volume":"8","author":"Dostalova","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.tox.2019.03.009_bib0055","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/IJN.S130267","article-title":"Apoferritin as an ubiquitous nanocarrier with excellent shelf life","volume":"12","author":"Dostalova","year":"2017","journal-title":"Int. J. Nanomed. Nanosurg."},{"key":"10.1016\/j.tox.2019.03.009_bib0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-2952(02)01072-9","article-title":"Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes","volume":"64","author":"Frei","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2019.03.009_bib0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s007750050143","article-title":"X-ray structure of recombinant horse L-chain apoferritin at 2.0 angstrom resolution: implications for stability and function","volume":"2","author":"Gallois","year":"1997","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1568011043482070","article-title":"Extending nature\u2019s leads: the anticancer agent ellipticine","volume":"4","author":"Garbett","year":"2004","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.tox.2019.03.009_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","article-title":"Nanoparticles for drug delivery: the need for precision in particle size parameters","volume":"69","author":"Gaumet","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tox.2019.03.009_bib0080","doi-asserted-by":"crossref","first-page":"14953","DOI":"10.1039\/C4CP01783H","article-title":"Excited state proton transfer dynamics of an eminent anticancer drug, ellipticine, in octyl glucoside micelle","volume":"16","author":"Gavvala","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.tox.2019.03.009_bib0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jiec.2014.11.017","article-title":"Role of biogenic silver nanoparticles in disruption of cell-cell adhesion in Staphylococcus aureus and Escherichia coli biofilm","volume":"26","author":"Goswami","year":"2015","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0090","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2217\/nnm.14.119","article-title":"Apoferritin applications in nanomedicine","volume":"9","author":"Heger","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.tox.2019.03.009_bib0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3892\/ijo.2015.3066","article-title":"Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells","volume":"47","author":"Hrabeta","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tox.2019.03.009_bib0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0014-5793(71)80571-9","article-title":"A simple procedure for the isolation of rat liver microsomes","volume":"17","author":"Kamath","year":"1971","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tox.2019.03.009_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-61779-108-6_6","article-title":"The xCELLigence system for real-time and label-free monitoring of cell viability","volume":"740","author":"Ke","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2019.03.009_bib0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1166\/jbn.2012.1406","article-title":"A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex","volume":"8","author":"Kilic","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.tox.2019.03.009_bib0115","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2019.03.009_bib0120","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/bm200026v","article-title":"pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly","volume":"12","author":"Kim","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.tox.2019.03.009_bib0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pharmthera.2011.07.006","article-title":"Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances","volume":"133","author":"Kizek","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tox.2019.03.009_bib0130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bcp.2011.06.003","article-title":"Cytochrome b5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy","volume":"82","author":"Kotrbov\u00e1","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2019.03.009_bib0135","series-title":"Study of Expression of Transferrin Receptors (TfR1) and their Utilization in Nanomedicine (in Czech)","author":"Krausova","year":"2017"},{"key":"10.1016\/j.tox.2019.03.009_bib0140","first-page":"10","article-title":"Liposomes: a novel drug delivery system","volume":"3","author":"Kulkarni","year":"2011","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"10.1016\/j.tox.2019.03.009_bib0145","doi-asserted-by":"crossref","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tox.2019.03.009_bib0150","doi-asserted-by":"crossref","first-page":"29461","DOI":"10.1038\/srep29461","article-title":"Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2019.03.009_bib0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/toxsci\/kfq206","article-title":"Glycosylation protects proteins against free radicals generated from toxic xenobiotics","volume":"117","author":"Mart\u00ednek","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0160","doi-asserted-by":"crossref","first-page":"e106974","DOI":"10.1371\/journal.pone.0106974","article-title":"L-ferritin binding to SCARA5: a new iron traffic pathway potentially implicated in retinopathy","volume":"9","author":"Mendes-Jorge","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tox.2019.03.009_bib0165","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1039\/C4CS00487F","article-title":"Nanoparticle colloidal stability in cell culture media and impact on cellular interactions","volume":"44","author":"Moore","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tox.2019.03.009_bib0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4161\/cc.9.2.10475","article-title":"The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks","volume":"9","author":"Nakamura","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tox.2019.03.009_bib0175","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuint.2011.08.018","article-title":"Transferrin receptor-1 suppresses neurite outgrowth in euroblastoma Neuro2A cells","volume":"60","author":"Nakamura","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.tox.2019.03.009_bib0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tox.2019.03.009_bib0185","doi-asserted-by":"crossref","first-page":"e1800011","DOI":"10.1002\/mabi.201800011","article-title":"Paclitaxel-loaded polylactide\/polyethylene glycol fibers with long-term antitumor activity as a potential drug carrier for local chemotherapy","volume":"18","author":"Plch","year":"2018","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.tox.2019.03.009_bib0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.canlet.2006.12.037","article-title":"DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells","volume":"252","author":"Poljakov\u00e1","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tox.2019.03.009_bib0195","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.bcp.2009.01.021","article-title":"The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells","volume":"77","author":"Poljakov\u00e1","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2019.03.009_bib0200","first-page":"101","article-title":"Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma","volume":"32","author":"Poljakova","year":"2011","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.tox.2019.03.009_bib0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1349-7006.2011.02137.x","article-title":"Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells","volume":"103","author":"Proch\u00e1zka","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0210","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.3390\/s121114792","article-title":"Modern micro and nanoparticle-based imaging techniques","volume":"12","author":"Ryvolova","year":"2012","journal-title":"Sensors"},{"key":"10.1016\/j.tox.2019.03.009_bib0215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/978-1-62703-529-3_21","article-title":"\u00b3\u00b2P-postlabeling analysis of DNA adducts","volume":"1044","author":"Schmeiser","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2019.03.009_bib0220","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1016\/j.bmc.2013.07.038","article-title":"Fine tuning of the pH-dependent drug release rate from polyHPMA-ellipticinium conjugates","volume":"21","author":"Sedlacek","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0225","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/978-1-61779-998-3_40","article-title":"Histone H2AX phosphorylation: a marker for DNA damage","volume":"920","author":"Sharma","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2019.03.009_bib0230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/09298673113206660272","article-title":"Ellipticines as DNA-targeted chemotherapeutics","volume":"21","author":"Stiborova","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0235","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0006-2952(01)00806-1","article-title":"The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts","volume":"62","author":"Stiborov\u00e1","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2019.03.009_bib0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ijc.11511","article-title":"DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling","volume":"107","author":"Stiborov\u00e1","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tox.2019.03.009_bib0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx0200818","article-title":"Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans","volume":"16","author":"Stiborov\u00e1","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2019.03.009_bib0250","doi-asserted-by":"crossref","first-page":"8374","DOI":"10.1158\/0008-5472.CAN-04-2202","article-title":"The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide","volume":"64","author":"Stiborov\u00e1","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2019.03.009_bib0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5507\/bp.2006.002","article-title":"Molecular mechanism of antineoplastic action of an anticancer drug ellipticine","volume":"150","author":"Stiborov\u00e1","year":"2006","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech."},{"key":"10.1016\/j.tox.2019.03.009_bib0260","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.22247","article-title":"Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine","volume":"120","author":"Stiborov\u00e1","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tox.2019.03.009_bib0265","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tox.2007.03.026","article-title":"Formation and persistence of DNA adducts of anticancer drug ellipticine in rats","volume":"236","author":"Stiborov\u00e1","year":"2007","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2019.03.009_bib0270","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.taap.2007.09.017","article-title":"Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse","volume":"226","author":"Stiborov\u00e1","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2019.03.009_bib0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbapap.2010.05.016","article-title":"Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency","volume":"1814","author":"Stiborov\u00e1","year":"2011","journal-title":"Biochim. Biophys. Acta \u2013 Proteins Proteom."},{"key":"10.1016\/j.tox.2019.03.009_bib0280","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/tx3000335","article-title":"Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases","volume":"25","author":"Stiborov\u00e1","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2019.03.009_bib0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tox.2012.08.004","article-title":"Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5","volume":"302","author":"Stiborov\u00e1","year":"2012","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2019.03.009_bib0290","doi-asserted-by":"crossref","first-page":"22982","DOI":"10.3390\/s141222982","article-title":"Formation of DNA adducts by ellipticine and its micellar form in rats\u2014a comparative study","volume":"14","author":"Stiborova","year":"2014","journal-title":"Sensors"},{"key":"10.1016\/j.tox.2019.03.009_bib0295","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/S1452-3981(23)08197-X","article-title":"Expression levels of enzymes metabolizing an anticancer drug ellipticine determined by electromigration assays influence its cytotoxicity to cancer cells\u2014a comparative study","volume":"9","author":"Stiborov\u00e1","year":"2014","journal-title":"Int. J. Electrochem. Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0300","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/ijms16010284","article-title":"The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, hepatic cytochrome P450 reductase null (HRN\u2122) mice and pure enzymes","volume":"16","author":"Stiborov\u00e1","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2019.03.009_bib0305","first-page":"22","article-title":"Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro","volume":"36","author":"Stiborova","year":"2015","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.tox.2019.03.009_bib0310","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00706-017-1986-9","article-title":"Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine","volume":"148","author":"Stiborov\u00e1","year":"2017","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0315","first-page":"753","article-title":"Multi responsive polymer micelles as ellipticine delivery carriers for cancer therapy","volume":"35","author":"Studenovsk\u00fd","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tox.2019.03.009_bib0320","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.nano.2015.07.015","article-title":"Design considerations for nanotherapeutics in oncology","volume":"11","author":"Stylianopoulos","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.tox.2019.03.009_bib0325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cossms.2012.10.001","article-title":"Clinical translation of nanomedicines","volume":"16","author":"Svenson","year":"2012","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0330","first-page":"848","article-title":"Theranostics: are we there yet? Mol","volume":"10","author":"Svenson","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tox.2019.03.009_bib0335","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1016\/S1452-3981(23)13296-2","article-title":"Electrochemical behaviour of doxorubicin encapsulated in apoferritin","volume":"8","author":"Tmejova","year":"2013","journal-title":"Int. J. Electrochem. Sci."},{"key":"10.1016\/j.tox.2019.03.009_bib0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/18715206113139990316","article-title":"Electrochemical study of ellipticine interaction with single and double stranded oligonucleotides","volume":"14","author":"Tmejova","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.tox.2019.03.009_bib0345","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/adma.200601168","article-title":"Biological containers: protein cages as multifunctional nanoplatforms","volume":"19","author":"Uchida","year":"2007","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tox.2019.03.009_bib0350","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.nano.2016.01.008","article-title":"Arginine-rich ionic complementary peptides as potential drug carriers: impact of peptide sequence on size, shape and cell specificity","volume":"12","author":"Wan","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.tox.2019.03.009_bib0355","first-page":"3221","article-title":"Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo","volume":"7","author":"Wu","year":"2012","journal-title":"Int. J. Nanomed. Nanosurg."},{"key":"10.1016\/j.tox.2019.03.009_bib0360","doi-asserted-by":"crossref","first-page":"e1325","DOI":"10.1371\/journal.pone.0001325","article-title":"Modification of hydrophilic and hydrophobic surfaces using an ionic-complementary peptide","volume":"19","author":"Yang","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.tox.2019.03.009_bib0365","first-page":"148","article-title":"Effect of cholesterol on cellular uptake of cancer drugs pirarubicin and ellipticine","volume":"120","author":"Zhang","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.tox.2019.03.009_bib0370","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1021\/acs.langmuir.8b03175","article-title":"Histidine-rich cell-penetrating peptide for cancer drug delivery and its uptake mechanism","volume":"35","author":"Zhang","year":"2019","journal-title":"Langmuir"},{"key":"10.1016\/j.tox.2019.03.009_bib0375","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/0006-2952(82)90560-3","article-title":"Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium","volume":"31","author":"Zwelling","year":"1982","journal-title":"Biochem. Pharm."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18306619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18306619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:43:28Z","timestamp":1778629408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X18306619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":75,"alternative-id":["S0300483X18306619"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2019.03.009","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}